Nektar R&D chief sells 186 shares at $71.98

NEKTAR THERAPEUTICS (NKTR) reported that Chief R&D Officer Jonathan Zalevsky sold 186 shares of common stock on August 18, 2026 at a weighted-average price of $71.98 per share.

Rhea-AI Filing Summary

NEKTAR THERAPEUTICS (NKTR) reported that Chief R&D Officer Jonathan Zalevsky sold 186 shares of common stock on August 18, 2026 at a weighted-average price of $71.98 per share. The sale was made solely to cover required tax withholding upon RSU vesting and is not a discretionary trade. After this sale, he holds 9,570 shares of NKTR common stock directly.

Insider Trade Summary

Net Seller: 186 shares

Net Sell 1 txn

Insider Zalevsky Jonathan

Role Chief R&D Officer

Sold 186 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	186	$71.98	$13K

Holdings After Transaction: Common Stock — 9,570 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
2. F2. This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Key Figures

Shares sold: 186 shares Weighted average sale price: $71.98 per share Shares following transaction: 9,570 shares +1 more

4 metrics

Shares sold 186 shares Common stock sale on August 18, 2026 to cover tax withholding

Weighted average sale price $71.98 per share Common stock sale on August 18, 2026, with trades from $71.78 to $72.49

Shares following transaction 9,570 shares Direct NKTR common stock holdings after the reported sale

Net shares sold in filing 186 shares Net sell direction across all reported transactions

Key Terms

restricted stock units, tax withholding obligations, weighted average sale price

3 terms

restricted stock units financial

"in connection with the vesting of the RSUs held by the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares sold by the reporting person to cover required tax withholding obligations"

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NKTR report for Jonathan Zalevsky?

Jonathan Zalevsky, Chief R&D Officer of NKTR, reported a sale of 186 shares of common stock on August 18, 2026 at a weighted-average price of $71.98 per share.

Was the August 18, 2026 NKTR stock sale by Jonathan Zalevsky a discretionary trade?

No. The filing states the 186 shares were sold to cover required tax withholding obligations related to vesting RSUs and "does not represent a discretionary trade" by Jonathan Zalevsky.

How many NKTR shares does Jonathan Zalevsky hold after this Form 4 transaction?

Following the sale to cover taxes, Jonathan Zalevsky directly holds 9,570 shares of NEKTAR THERAPEUTICS common stock.

What price was received in the NKTR insider sale on August 18, 2026?

The reported price is a weighted average sale price of $71.98 per share, with individual trade prices ranging from $71.78 to $72.49.

Was the NKTR insider transaction executed under a Rule 10b5-1 trading plan?

No. The Rule 10b5-1 checkbox is not marked as being under a plan, and the footnotes describe the sale as covering required tax withholding for RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2026 - 07:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zalevsky Jonathan

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S		186(1)	D	$71.98(2)	9,570	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)